EE05442B1 - V„ikeses annuses entekaviiri sisaldav ravimkoostis B-hepatiidi viirusinfektsiooni raviks ning meetod selle valmistamiseks - Google Patents

V„ikeses annuses entekaviiri sisaldav ravimkoostis B-hepatiidi viirusinfektsiooni raviks ning meetod selle valmistamiseks

Info

Publication number
EE05442B1
EE05442B1 EEP200200484A EEP200200484A EE05442B1 EE 05442 B1 EE05442 B1 EE 05442B1 EE P200200484 A EEP200200484 A EE P200200484A EE P200200484 A EEP200200484 A EE P200200484A EE 05442 B1 EE05442 B1 EE 05442B1
Authority
EE
Estonia
Prior art keywords
hepatitis
preparation
treatment
pharmaceutical composition
virus infection
Prior art date
Application number
EEP200200484A
Other languages
English (en)
Estonian (et)
Inventor
J. Colonno Richard
L. Sprockel Omar
Harianawala Abizer
S. Desai Divyakant
G. Fakes Michael
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26881354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05442(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of EE200200484A publication Critical patent/EE200200484A/xx
Publication of EE05442B1 publication Critical patent/EE05442B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
EEP200200484A 2000-02-29 2001-01-26 V„ikeses annuses entekaviiri sisaldav ravimkoostis B-hepatiidi viirusinfektsiooni raviks ning meetod selle valmistamiseks EE05442B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18567200P 2000-02-29 2000-02-29
US22131300P 2000-07-28 2000-07-28
PCT/US2001/002630 WO2001064221A1 (en) 2000-02-29 2001-01-26 Low dose entecavir formulation and use

Publications (2)

Publication Number Publication Date
EE200200484A EE200200484A (et) 2004-04-15
EE05442B1 true EE05442B1 (et) 2011-08-15

Family

ID=26881354

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200484A EE05442B1 (et) 2000-02-29 2001-01-26 V„ikeses annuses entekaviiri sisaldav ravimkoostis B-hepatiidi viirusinfektsiooni raviks ning meetod selle valmistamiseks

Country Status (35)

Country Link
US (1) US6627224B2 (sr)
EP (2) EP1267880B2 (sr)
JP (3) JP5140222B2 (sr)
KR (1) KR100757155B1 (sr)
AR (1) AR027965A1 (sr)
AT (1) ATE312613T1 (sr)
AU (1) AU2001229775A1 (sr)
BG (1) BG65815B1 (sr)
BR (1) BRPI0108435B8 (sr)
CA (1) CA2401569C (sr)
CO (1) CO5261593A1 (sr)
CZ (1) CZ303395B6 (sr)
DE (1) DE60115870T3 (sr)
DK (1) DK1267880T4 (sr)
EA (1) EA006181B1 (sr)
EE (1) EE05442B1 (sr)
EG (1) EG24408A (sr)
ES (1) ES2253403T5 (sr)
GE (1) GEP20053504B (sr)
HK (1) HK1048771A1 (sr)
HR (1) HRP20020649A2 (sr)
HU (1) HU230698B1 (sr)
IL (1) IL150447A0 (sr)
MX (1) MXPA02008359A (sr)
MY (1) MY127422A (sr)
NO (1) NO324014B1 (sr)
NZ (1) NZ520024A (sr)
PE (1) PE20020770A1 (sr)
PL (1) PL201411B1 (sr)
RS (1) RS51561B (sr)
SI (1) SI1267880T2 (sr)
SK (1) SK288008B6 (sr)
TW (1) TWI287988B (sr)
UA (1) UA84534C2 (sr)
WO (1) WO2001064221A1 (sr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH061291Y2 (ja) 1988-03-04 1994-01-12 株式会社日立工機原町 拘束状態解除装置付き丸鋸式切断機
AU2001229775A1 (en) * 2000-02-29 2001-09-12 Bristol-Myers Squibb Company Low dose entecavir formulation and use
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
KR20070120617A (ko) 2001-01-26 2007-12-24 쉐링 코포레이션 치환된 아제티딘온 화합물을 포함하는 약제학적 조성물
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
EP1429756B1 (en) 2001-09-21 2006-11-22 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
TWI275392B (en) * 2002-04-08 2007-03-11 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
CA2504916A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
PL397715A1 (pl) 2002-12-11 2012-03-26 Bristol-Myers Squibb Company Pochodna cyklopentadienowa i sposób jej wytwarzania
PT1583542E (pt) 2003-01-14 2008-09-17 Gilead Sciences Inc Composições e métodos para terapia de combinação antiviral
WO2004081002A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
DE602004018617D1 (de) 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
WO2004081004A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
PT3138566T (pt) 2003-11-17 2022-02-02 Biomarin Pharm Inc Tratamento de fenilcetonúria com bh4
BRPI0416691A (pt) * 2003-11-18 2007-01-30 Boehringer Ingelheim Int forma de preparação farmacêutica sólida
US7511139B2 (en) * 2004-06-04 2009-03-31 Bristol-Myers Squibb Company Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
JP4756153B2 (ja) * 2004-08-27 2011-08-24 富士製薬工業株式会社 低成分含量の錠剤の製造方法
MX2007003519A (es) * 2004-09-23 2007-08-07 Fmc Corp Composicion de recubrimiento.
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
CN101245068A (zh) * 2007-02-14 2008-08-20 浙江医药股份有限公司新昌制药厂 结晶型态的恩替卡韦及其制备方法和其药物组合物及用途
TW200904405A (en) * 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
EP2493454A2 (en) 2009-10-28 2012-09-05 McNeil-PPC, Inc. Fast dissolving/disintegrating coating compositions
WO2011076412A1 (de) 2009-12-23 2011-06-30 Ratiopharm Gmbh Orale darreichungsform umfassend entecavir
DE102009060194A1 (de) 2009-12-23 2011-06-30 ratiopharm GmbH, 89079 Orale Darreichungsform umfassend Entecavir
WO2011103516A2 (en) * 2010-02-18 2011-08-25 The Trustees Of Princeton University Inhibitors of long and very long chain fatty acid metabolism as broad spectrum anti-virals
AU2011235227B2 (en) 2010-03-31 2016-09-08 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
WO2012048455A1 (zh) * 2010-10-12 2012-04-19 武汉大学 一种抗病毒透皮吸收贴片及其制备方法
EP2508172A1 (en) 2011-04-06 2012-10-10 Zentiva, a.s. Stable and uniform formulations of entecavir and preparation method thereof
KR101594820B1 (ko) * 2011-06-16 2016-02-17 건일제약 주식회사 엔테카비르를 함유하는 미립구 및 이의 제조방법
KR101439635B1 (ko) 2011-11-01 2014-09-11 대원제약주식회사 안정성이 향상된 엔테카비어를 함유하는 약학적 조성물 및 그 제조방법
EP2780001A4 (en) * 2011-11-14 2015-10-28 Hetero Research Foundation SOLID ORAL ENTECAVIR COMPOSITIONS WITH FAST RELEASE
EP2644197A1 (en) * 2012-03-26 2013-10-02 Sanovel Ilac Sanayi ve Ticaret A.S. Novel Pharmaceutical Compositions of Entecavir
EP2644196B1 (en) * 2012-03-26 2019-09-18 Arven Ilac Sanayi ve Ticaret A.S. Pharmaceutical compositions of Entecavir
KR101285008B1 (ko) * 2012-04-18 2013-07-10 제일약품주식회사 저용량 엔테카비어의 경구투여 제제의 제조방법
CA2779052A1 (en) * 2012-05-31 2013-11-30 Pharmascience Inc. Pharmaceutical composition of entecavir and process of manufacturing
CN103908436B (zh) * 2012-12-29 2016-02-10 安徽贝克生物制药有限公司 一种速释型恩替卡韦组合物
KR101512895B1 (ko) 2013-08-09 2015-04-16 대화제약 주식회사 엔테카비어를 포함하는 약학적 조성물의 제조방법
EP3158998A4 (en) * 2014-06-20 2018-02-14 CTC Bio, Inc. Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
JP6625878B2 (ja) * 2015-01-26 2019-12-25 沢井製薬株式会社 エンテカビル含有錠剤、その製造方法及びそれを用いた口腔内崩壊錠
WO2017057147A1 (ja) * 2015-09-30 2017-04-06 株式会社ダイセル 易服用性固形製剤用粒子組成物及び該粒子組成物を含む易服用性固形製剤
EP4029503B1 (en) 2019-09-29 2026-01-28 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Drug combinations of entecavir and a tlr7 agonist for use in the treatment of hbv
WO2022206752A1 (zh) * 2021-03-29 2022-10-06 正大天晴药业集团股份有限公司 Toll样受体7激动剂和抗PD-L1抗体的药物联合
KR102940556B1 (ko) 2022-01-21 2026-03-16 한림대학교 산학협력단 피루브산 및 pdk 억제제를 포함하는 뇌질환의 예방 또는 치료용 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3836618A (en) * 1971-12-23 1974-09-17 American Home Prod Process for the uniform distribution of a drug on a granulated base
US4513008A (en) * 1982-07-30 1985-04-23 The Vinoxen Company, Inc. Virucidal compositions and therapy
US4489026A (en) * 1982-09-07 1984-12-18 The Upjohn Company Process for preparing solid unit dosage forms of ultra-low dose drugs
US4631284A (en) * 1984-11-19 1986-12-23 Mallinckrodt, Inc. Acetaminophen compositions containing low doses of chlorpheniramine maleate, method for preparing same and tablets formed therefrom
US5206244A (en) 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
JPH08208478A (ja) * 1994-10-14 1996-08-13 Japan Energy Corp 抗エイズ薬製剤およびその製造方法
ATE243500T1 (de) * 1996-04-04 2003-07-15 Felix Specht Verfahren zur herstellung von gering dosierten freifliessenden und/oder direktkomprimierbaren pulversystemen
AU4090697A (en) 1996-09-03 1998-03-26 Bristol-Myers Squibb Company Improved process for preparing the antiviral agent {1s-(1alpha, 3alpha, 4beta)}-2-amino-1,9-dihydro-9-{4-hydroxy-3-(hydroxymethyl)-2 -methylenecyclopentyl}-6h-purin-6-one
US6395716B1 (en) * 1998-08-10 2002-05-28 Novirio Pharmaceuticals Limited β-L-2′-deoxy-nucleosides for the treatment of hepatitis B
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
GB9820417D0 (en) 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
GB9820420D0 (en) 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
GB9820416D0 (en) 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US6432966B2 (en) † 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
AU2001229775A1 (en) * 2000-02-29 2001-09-12 Bristol-Myers Squibb Company Low dose entecavir formulation and use

Also Published As

Publication number Publication date
EP1267880B1 (en) 2005-12-14
EP1267880A1 (en) 2003-01-02
CA2401569C (en) 2009-08-18
TWI287988B (en) 2007-10-11
SI1267880T2 (sl) 2010-04-30
BRPI0108435B1 (pt) 2019-02-05
JP2015178523A (ja) 2015-10-08
DE60115870T2 (de) 2006-08-17
AU2001229775A1 (en) 2001-09-12
BG106905A (bg) 2003-04-30
YU63002A (sh) 2005-03-15
JP5921746B2 (ja) 2016-05-24
EG24408A (en) 2009-05-20
HU230698B1 (hu) 2017-09-28
US6627224B2 (en) 2003-09-30
BR0108435A (pt) 2004-06-15
CA2401569A1 (en) 2001-09-07
PE20020770A1 (es) 2002-09-06
EA006181B1 (ru) 2005-10-27
CO5261593A1 (es) 2003-03-31
NO20024099L (no) 2002-08-28
EA200200812A1 (ru) 2003-12-25
MY127422A (en) 2006-11-30
GEP20053504B (en) 2005-05-10
JP5140222B2 (ja) 2013-02-06
EE200200484A (et) 2004-04-15
DK1267880T4 (da) 2010-05-17
EP1267880B2 (en) 2010-01-20
PL366102A1 (en) 2005-01-24
US20010033864A1 (en) 2001-10-25
RS51561B (sr) 2011-08-31
SK288008B6 (sk) 2012-10-02
AR027965A1 (es) 2003-04-16
ATE312613T1 (de) 2005-12-15
MXPA02008359A (es) 2003-02-12
BG65815B1 (bg) 2010-01-29
EP1642582A1 (en) 2006-04-05
DE60115870T3 (de) 2010-07-29
CZ303395B6 (cs) 2012-08-29
KR20020082230A (ko) 2002-10-30
KR100757155B1 (ko) 2007-09-07
UA84534C2 (uk) 2008-11-10
HK1048771A1 (zh) 2003-04-17
NZ520024A (en) 2005-03-24
DE60115870D1 (de) 2006-01-19
IL150447A0 (en) 2002-12-01
SK11652002A3 (sk) 2003-09-11
HUP0500558A2 (hu) 2005-09-28
HUP0500558A3 (en) 2012-08-28
SI1267880T1 (sl) 2006-06-30
WO2001064221A1 (en) 2001-09-07
DK1267880T3 (da) 2006-03-06
ES2253403T5 (es) 2010-04-22
ES2253403T3 (es) 2006-06-01
JP2004503467A (ja) 2004-02-05
NO20024099D0 (no) 2002-08-28
HRP20020649A2 (en) 2004-12-31
JP2012255017A (ja) 2012-12-27
NO324014B1 (no) 2007-07-30
PL201411B1 (pl) 2009-04-30
BRPI0108435B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
IL215891A (en) Hepatitis C Serine Protease Inhibitors, Pharmaceutical Compounds Containing Them, and Their Use in Preparing Drugs to Treat Hepatitis C Infections
EA200200812A1 (ru) Фармацевтическая композиция, содержащая низкую дозу энтекавира, и ее применение
TR200402565T4 (tr) Hepatit delta virüsü enfeksiyonunun tedavi edilmesinde ß-L-2'-deoksi-nükleosidlerin kullanımı
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
AP2002002704A0 (en) Methods and compositions for treating hepatitis c virus
WO2003051306A3 (en) N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
EE200300151A (et) Ravimitena kasutatavad antikolinergikumid ning meetodid nende valmistamiseks
GB2355932B (en) A pharmaceutical formulation suitable for the treatment of hepatitis B, hepatitis C and other viral infections of the liver and a process for its preparation
EP1307130A4 (en) VACCINE AGAINST HUMAN IMMUNE WEAK VIRUS
AU2002346686A1 (en) Compositions and method for treating hepatitis virus infection
IL162236A0 (en) Purified hepatitis c virus envelopeproteins for dagnostic and therapeutic use
EP1357940A4 (en) HEPATITIS? B? VIRUS THERAPY
DE60123042D1 (de) L-fmau zur behandlung von hepatitis-delta-virus-infizierung
AU2002219881A1 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
NO20041855L (no) Fremgangsmate for behandling av hepatitt C-virusinfeksjon ved behandling av feilpasienter
AU2001269092A1 (en) Inhibitors of hepatitis b virus infection
IL161138A0 (en) Treatment of hepatitis b virus infection with human monoclonal antibodies
IL236510A0 (en) Use of one or more hbv antigens for the preparation of oral pharmaceutical compositions for treating a subject having an active hbv infection or hepatocellular carcinoma
NO20041685L (no) Fremgangsmate for behandling av hepatitt C-virusinfeksjon hos pasienter med manglende behandlingsrespons
AU2001234596A1 (en) Use of castanospermine and substituted-castanospermine compounds for treating hepatitis virus infections
IL151033A0 (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
EE04941B1 (et) Ravimid skisofreenia ennetamiseks ja raviks ning nende valmistamine
AU2001277055A1 (en) Composition for treatment of and method of monitoring hepatitis c virus using interferon-tau
DK1180041T3 (da) Vaccine med ISA-virus
AU2003299493A8 (en) Compositions and methods for the treatment of hepatitis c virus infection

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
HE1A Change of address